» Articles » PMID: 25542827

Variation in Levels of the Lung Carcinogen NNAL and Its Glucuronides in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer

Overview
Date 2014 Dec 28
PMID 25542827
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Results of the Multiethnic Cohort (MEC) study demonstrated that, for the same quantity of cigarettes smoked, African Americans and Native Hawaiians have a higher risk of lung cancer compared with whites, whereas Latinos and Japanese Americans have a lower risk. We hypothesize that the uptake and/or metabolism of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) could explain the differences in lung cancer risk.

Methods: We measured urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronides and their sum (total NNAL), biomarkers of NNK uptake, in 2,252 smokers from the MEC. Ethnic-specific geometric means were compared adjusting for age at urine collection, sex, creatinine and total nicotine equivalents, a marker of total nicotine uptake.

Results: African Americans had the highest median total NNAL levels (1.80 pmol/mL urine) and Japanese Americans had the lowest (0.914 pmol/mL urine), with intermediate values in the other three groups. Geometric mean of total NNAL in African Americans was also highest, and in Japanese Americans it was lowest; Japanese American geometric mean was statistically different from whites (P = 0.004).

Conclusions: African Americans had higher levels of total NNAL per mL urine than whites, while Japanese Americans had lower levels, consistent with lung cancer risk among smokers in these groups. However, our data were not consistent with the high and low lung cancer risks of Native Hawaiian and Latino smokers, respectively.

Impact: The higher lung cancer susceptibility of African-American smokers and the lower susceptibility of Japanese-American smokers compared with whites can be explained in part by exposure to the potent lung carcinogen NNK. Cancer Epidemiol Biomarkers Prev; 24(3); 561-9. ©2014 AACR.

Citing Articles

Tobacco Biomarkers by Latino Heritage and Race, US, 2007 to 2014 National Health and Nutrition Examination Survey.

Duong C, Rodriquez E, Hinerman A, Hooshmand S, Claudel S, Benowitz N Cancer Epidemiol Biomarkers Prev. 2024; 33(12):1586-1597.

PMID: 39348098 PMC: 11611627. DOI: 10.1158/1055-9965.EPI-24-0744.


Association of Urinary Biomarkers of Tobacco Exposure with Lung Cancer Risk in African American and White Cigarette Smokers in the Southern Community Cohort Study.

Murphy S, Guillermo C, Thomson N, Carmella S, Wittmann M, Aldrich M Cancer Epidemiol Biomarkers Prev. 2024; 33(8):1073-1082.

PMID: 38780906 PMC: 11299762. DOI: 10.1158/1055-9965.EPI-23-1362.


Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer.

Jung S, Papp J, Sobel E, Pellegrini M, Yu H Endocr Relat Cancer. 2023; 30(4).

PMID: 36705562 PMC: 10095926. DOI: 10.1530/ERC-22-0184.


Association of Urinary Biomarkers of Smoking-Related Toxicants with Lung Cancer Incidence in Smokers: The Multiethnic Cohort Study.

Cigan S, Murphy S, Stram D, Hecht S, Le Marchand L, Stepanov I Cancer Epidemiol Biomarkers Prev. 2022; 32(3):306-314.

PMID: 36350738 PMC: 9992134. DOI: 10.1158/1055-9965.EPI-22-0569.


Suppressing the activation of protein kinase A as a DNA damage-independent mechanistic lead for dihydromethysticin prophylaxis of NNK-induced lung carcinogenesis.

Bian T, Ding H, Wang Y, Hu Q, Chen S, Fujioka N Carcinogenesis. 2022; 43(7):659-670.

PMID: 35353881 PMC: 9653071. DOI: 10.1093/carcin/bgac031.


References
1.
Schwartz A, Swanson G . Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan. Cancer. 1997; 79(1):45-52. DOI: 10.1002/(sici)1097-0142(19970101)79:1<45::aid-cncr7>3.0.co;2-l. View

2.
Hecht S . Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis. 2002; 23(6):907-22. DOI: 10.1093/carcin/23.6.907. View

3.
Derby K, Cuthrell K, Caberto C, Carmella S, Murphy S, Hecht S . Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer. Int J Cancer. 2009; 125(10):2418-24. PMC: 2779778. DOI: 10.1002/ijc.24585. View

4.
Haiman C, Stram D, Wilkens L, Pike M, Kolonel L, Henderson B . Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006; 354(4):333-42. DOI: 10.1056/NEJMoa033250. View

5.
Richie Jr J, Carmella S, Muscat J, SCOTT D, Akerkar S, Hecht S . Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiol Biomarkers Prev. 1997; 6(10):783-90. View